Background {#Sec1}
==========

Infection with human papillomavirus (HPV) is a cause of many diseases including cervical cancer. About 90 types of human papillomavirus have been found but two types (16 and 18) are responsible for 75% to 80% of cases of cervical cancer in Europe and North America \[[@CR1]\], and more than 70% of cases in Asia \[[@CR2]\]. In 2012, cervical cancer was the fourth most common type of cancer among women worldwide with an estimated 528,000 new cases and 266,000 deaths; 87% of deaths occurred in low and middle-income countries \[[@CR3]\]. Treatment costs for cervical cancer remain high with low survival probabilities due to late diagnosis in many countries \[[@CR4], [@CR5]\]. HPV vaccines offer an approach for primary prevention of HPV infection that can eventually reduce the health and economic burden of cervical cancer. Cost-effectiveness studies in many countries using a range of model types have suggested that vaccinating young adolescent females can be cost-effective \[[@CR6]--[@CR12]\].

In Vietnam, there are no comprehensive national figures on cervical cancer incidence. However, studies based on smaller samples from older registry-based studies have found that incidence ranged from 6.8 cases per 100,000 women in the north of Vietnam \[[@CR13]\] to 26 cases per 100,000 women in the south of Vietnam \[[@CR14]\]. As estimated, cervical cancer is the main cause of female cancer mortality Ho Chi Minh City and the second main cause in Hanoi \[[@CR15]\].

Vietnam began its accelerated transition policy from support from Gavi, the Vaccine Alliance, in 2016 \[[@CR16]\]. While the country is no longer eligible for Gavi support, there is a window of opportunity where is can still procure vaccines at Gavi prices \[[@CR17]\]. The Vietnam National Institute of Hygiene and Epidemiology (NIHE) remains keen on introducing additional vaccines despite tight resource constraints. Vietnam has not yet incorporated HPV vaccines into its routine vaccination schedule, although pilot studies have been conducted in the country \[[@CR18]\]. A previous cost-effectiveness analysis concluded that HPV vaccination combined with regular screening could be cost-effective provided that vaccine prices were low (below I\$25 per vaccinated girl) \[[@CR19]\]. However, there has yet to be a cost-effectiveness study on HPV vaccination involving local analysts and stakeholders. There has also not been a study estimating the cost of cervical cancer and pre-cancer treatment in Vietnam, as the previous study extrapolated costing data from Thailand and other countries. Hence we aimed to perform the first local cost-effectiveness analysis of human papillomavirus vaccines in Vietnam using the Papillomavirus Rapid Interface for Modeling and Economics (PRIME).

Methods {#Sec2}
=======

Mathematical model {#Sec3}
------------------

We used PRIME, a static model supported by the World Health Organization to facilitate estimating the cost-effectiveness of HPV vaccine introduction in order to support decisions about vaccine introduction, particularly in low and middle-income countries. An Excel-based interface to PRIME is available in the public domain ([www.primetool.org](http://www.primetool.org/)) for country studies. This consists of a number of spreadsheets to input country-level data on demography, cervical cancer incidence and mortality, and costs. Outputs can be visualised in terms of tables and graphs. The Excel-based version of the model can be used to evaluate the cost-effectiveness of vaccinating females prior to sexual debut. Because it excludes herd effects and details of cancer natural history, it is not designed to evaluate other options such as vaccinating males, vaccinating older females, catch-up campaigns or changes to cervical cancer screening. The detailed model structure and assumptions have been previously described \[[@CR20]\].

Methodological assumptions {#Sec4}
--------------------------

Methodological assumptions used in the analysis followed WHO guidelines for cost-effectiveness evaluations \[[@CR21]\]. In particular, we adopted a a discount rate of 3% for both costs and health effects on a lifetime time horizon. However, a health care provider perspective was adopted because of the unavailability of household expenses for cervical cancer patients in Vietnam. Health outcomes were measured in disability-adjusted life years (DALYs) rather than quality-adjusted life years (QALYs) because quality of life weights associated with cervical cancer have never been elicited from a Vietnamese population.

PRIME's default data (obtained from publicly available databases and the literature) were used to inform parameters related to vaccine efficacy, population demography and cervical cancer incidence \[[@CR20]\]. However, costs for vaccine delivery and cervical cancer treatment were estimated from primary sources.

Vaccination assumptions {#Sec5}
-----------------------

School-based HPV vaccine demonstration projects organized by the Program for Appropriate Technology in Health (PATH) in Vietnam among 11 year olds achieved coverage of 96.1% \[[@CR22]\]. Hence we assumed that vaccination would be delivered to 11 year olds and achieve 95% coverage. The current HPV vaccine schedule recommended by NIHE is three doses.

Vaccine delivery costs {#Sec6}
----------------------

We conducted a costing study which used a bottom-up approach to calculate the financial cost of HPV vaccine delivery from central to commune level (i.e. between NIHE in Hanoi, the provincial centers for preventive medicine, the district health centers, and the commune health station), incorporating both capital costs and recurrent costs. We also assumed minimal wastage of vaccine doses, due to annual training of vaccine delivery staff and use of single-dose vials in the Vietnamese national immunization program.

Financial costs estimated included both start-up and recurrent costs. Start-up costs were defined as initial investments whose benefits last longer than one year such as initial training, social mobilization, information, education and communication material development, cold chain equipment purchase and vehicles purchase. Recurrent costs were defined as the cost of resources whose benefits last one year or less such as the personnel time, transport, maintenance, monitoring and evaluation, and supervision as well as costs of short-term training activities that lasted a year or less.

Costs for healthcare personnel for each activity was estimated based on their time and monthly salary. To collect information related to these personnel costs, one staff member at each health facility was interviewed and monthly salary reports were collected. For start-up costs, we assumed a discount rate of 3% and useful lifecycle of 5-10 years.

Treatment costs {#Sec7}
---------------

To estimate the cost of pre-cancer and cancer treatment, we conducted a study involving clinician and patient interviews, and hospital record reviews. This consisted of two phases.

Hospitals and health centers in Vietnam are stratified into four levels: central, provincial, district and commune. While provincial and district hospitals provide some treatment of pre-cancerous neoplasias, cervical cancer treatment is only provided at the central level. We randomly selected two central hospitals (Ho Chi Minh City Cancer Hospital and Hue Central Hospital) from a list of all hospitals in Ho Chi Minh City and Hue.

In phase I of the study, we invited healthcare workers from the selected hospitals to construct scenarios that represent patient treatment situations (see Table [1](#Tab1){ref-type="table"}). In these hospitals, 40 staff from different departments (including examination, laboratory medicine, radiotherapy and chemotherapy) participated.Table 1Scenarios describing hospitalized cervical cancer patients for costing by the expert panelScenarioHospital levelDiagnosisType of treatmentLength of treatment (days)Number of days of productivity lossScenario 1Central, provincial and districtCIN IAnnual screening11Scenario 2Central, provincial and districtCIN ICryo therapy23Scenario 3Central and provincialCIN II & IIILEEP45Scenario 4Central and provincialCIN II &IIIConization45Scenario 5At central levelIA1 - IIB proximalRadical hysterectomy77Scenario 6At central levelRadical hysterectomy + Chemoradiation30150Scenario 7At central levelRadical hysterectomy + Radio therapy (Intr)30150Scenario 8At central levelRadical hysterectomy + Radio-therapy (External beam)30150Scenario 9At central levelIIB distant - IVBChemoradiation30150Scenario 10At central levelRadio therapy (Intra + External)30150Scenario 11Average cost of scenario 5 to 10

In phase II, we micro-costed each of the scenarios identified by interviewing the healthcare workers in detail. In addition, we reviewed medical records and financial bills by randomly selecting 38 patients in the selected hospitals to extract information related to cancer stage, patient age, diagnosis, treatment and length of treatment. Further to that, we interviewed the 38 patients and their family members to get detailed costing information.

Sensitivity analysis {#Sec8}
--------------------

Model uncertainty was explored by varying parameters governing vaccine delivery and treatment costs according to the scenarios above. Vaccine prices were also varied between the Gavi negotiated price of United States Dollar (USD) 4.55 per dose, the market price of Cervarix in Vietnam of USD 35.60 per dose and the market price of Gardasil in Vietnam of USD 55.80 per dose.

Results {#Sec9}
=======

Table [2](#Tab2){ref-type="table"} shows the parameters used in the model, including birth cohort size, coverage of 3 vaccine doses, vaccine efficacy vs HPV 16/18, vaccine price per fully immunized girl, vaccine delivery cost per fully immunized girl, cancer treatment cost as per patient scenario, DALYs incurred due to non-fatal and fatal cancer episodes, and epidemiological data such as cervical cancer incidence and mortality. The female birth cohort size was 556,874 in 2014. Vaccine price per fully immunized girl was estimated to be USD 15-168. Cancer treatment cost for 10 patient scenarios ranged from USD 368-11448 depending on the kind of treatment. Information related to cervical cancer incidence and mortality was extracted from GLOBOCAN 2012. All-cause mortality in 2012 was extracted from national data.Table 2Selected parameters for estimating cost-effectiveness of HPV vaccination using the PRIME modelNoParameterAverage value/valueRangeSource1Vaccine delivery cost per FIG\$ 10.4\$ 9.5-\$ 11.3Costing study2Cancer treatment costCosting studyScenario 5 (IA1 - IIB proximal treated by Radical hysterectomy)\$ 368.3N/AScenario 6 (IA1 - IIB proximal treated by Radical hysterectomy + Chemoradiation)\$ 8700.1N/AScenario 7 (IA1 - IIB proximal treated by Radical hysterectomy + Radio therapy (Intr))\$ 2209.6N/AScenario 8 (IA1 - IIB proximal treated by Radical hysterectomy + Radio-therapy (External beam))\$ 1449.9N/AScenario 9 (IIB distant -- IVB treated by Chemoradiation)\$ 11448.1N/AScenario 10 (IIB distant -- IVB treated by Radio therapy (Intra + External))\$ 5166.52N/AScenario 11 (average cost of all scenarios)\$ 4,890.44N/A3DALYs lost per non-fatal cancer episode0.7Literature review4DALYs lost per fatal cancer episode (excluding life years lost)0.8Literature review5Epidemiological dataLiterature reviewCervical cancer incidence in 20126.1 per 100000GLOBOCAN 201220.5 per 10000026.7 per 10000031.3 per 10000032.1 per 10000026.2 per 10000020.5 per 10000013 per 100000Cervical cancer mortality in 20121.1 per 100000GLOBOCAN 20126.5 per 10000015.1 per 10000018.8 per 10000021.3 per 10000021.8 per 10000020 per 10000016.1 per 1000005.3 per 100000All-cause mortality in 2012100 - 52 800 per 100 000 (depending on age)National statistics

Table [3](#Tab3){ref-type="table"} compares the cost-effectiveness of HPV vaccination in Vietnam under different assumptions about the cost of cervical cancer treatment (depending on the type of treatment and stage of cancer) and the cost of vaccination. If HPV vaccines can be procured at prices negotiated by Gavi, then the incremental cost per DALY averted ranges between USD18 (under scenario 9) - USD1,103 (under scenario 5). However, if either vaccine is only available at list prices, then the incremental cost per DALY averted increases dramatically, exceeding USD4,000 in all the scenarios explored. Using the average cost of cancer treatment over the six scenarios gives an incremental cost per DALY of USD800 at Gavi prices, and over USD5,000 at list prices.Table 3Estimation of incremental costs as per life saved, per life year saved and per DALY averted in the PRIMEEstimation of incremental costsVaccine priceScenario 5Scenario 6Scenario 7Scenario 8Scenario 9Scenario 10Scenario 11 (average cost)Incremental cost per discounted life savedHPV vaccine with negotiated price from GAVI (13.65 US\$ for 3 doses)24,4905,77320,35422,06140113,71114,331Cervarix vaccine with 106.8 US\$ for 3 doses122,510103,793118,374120,08197,619111,731112,351Gardasil vaccine with 167.4 US\$ for 3 doses186,279167,561182,142183,849161,388175,499176,120Incremental cost per discounted life year savedHPV vaccine with negotiated price from GAVI (13.65 US\$ for 3 doses)1,1962829941,07720670700Cervarix vaccine with 106.8 US\$ for 3 doses5,9835,0695,7815,8654,7685,4575,487Gardasil vaccine with 167.4 US\$ for 3 doses9,0988,1848,8968,9797,8828,5718,602Incremental cost per discounted DALY avertedHPV vaccine with negotiated price from GAVI (13.65 US\$ for 3 doses)1,10326091799418618645Cervarix vaccine with 106.8 US\$ for 3 doses5,5184,6755,3315,4084,3975,0325,060Gardasil vaccine with 167.4 US\$ for 3 doses8,3907,5478,2038,2807,2697,9047,932Unit cost: US\$

Discussion {#Sec10}
==========

Our analysis suggests that routine HPV vaccination of 11-year-old girls in Vietnam has an incremental cost-effectiveness ratio of around USD780 - 1200 per DALY averted and USD7000 - 23000 per life saved, if the vaccine can be procured at prices available to Gavi, the Vaccine Alliance. This is well below Vietnam's Gross Domestic Product (GDP) per capita, and hence at the level commonly considered "very cost-effective" based on global recommendations in WHO-CHOICE.

There are large disparities in cervical cancer incidence between north and south Vietnam, so the cost-effectiveness of vaccination is likely to differ between regions. However, we have performed our analysis on a national level because the most recent cervical cancer incidence data is only available at the national-level, and because a national program is likely to be more acceptable to policy makers.

More recently, the use of GDP per capita-based thresholds for cost-effectiveness has been criticized \[[@CR25]\] and is no longer recommended by WHO. Several alternatives have been suggested, including comparing the incremental cost-effectiveness of new interventions to existing interventions, and measuring the willingness to pay for health improvements. In terms of the first approach, the cost per disability-adjusted life year (DALY) averted of HPV vaccination is similar to previously published figures for rotavirus (USD540 per DALY averted) \[[@CR23]\], and slightly lower than figures for Haemophilus influenza type b (USD1373 per DALY averted) \[[@CR24]\]. The cost per life saved is within the range of estimates for corresponding figures for existing vaccines in Vietnam's Expanded Programme on Immunization (USD1000 - 27,000 per life saved) \[[@CR26], [@CR27]\]. For the second approach, the only relevant study to refer to is one in a rural area of Vietnam in 2014. This revealed that respondents were willing to pay USD667 - 992 for a quality-adjusted life year (QALY) \[[@CR28]\]. The results would likely be higher if urban respondents were surveyed. Nevertheless, the results suggest that HPV vaccination is likely to be cost-effective in Vietnam if the country is able to access Gavi prices, but the cost-effectiveness would probably not be favourable if higher prices had to be paid.

A study conducted to assess Vietnamese mothers' willingness to pay for HPV vaccination for their daughters suggested that nearly 70% of them would pay for HPV vaccines at \$7 per course, but this drops to 30% at \$353 per course \[[@CR29]\]. This suggests that even at Gavi-negotiated prices, public procurement of HPV vaccines is necessary in order to see substantial vaccine uptake in the population.

If Vietnam is not eligible to purchase vaccine prices at Gavi-negotiated levels, then vaccination appears much less cost-effective than other vaccines, and its incremental cost-effectiveness ratio well exceeds GDP per capita. This highlights the value of pooled procurement mechanisms such as those used by Gavi and the Pan-American Health Organization (PAHO) in obtaining fair prices in low- and lower-middle income countries \[[@CR30]\]. It also underscores the urgency of HPV vaccine introduction in Gavi-graduating countries like Vietnam while they are still eligible for lower vaccine prices. Analyses such as these are also helpful to local policy makers for negotiating long-term prices with vaccine manufacturers. Further analyses could take into account constraints of both cost-effectiveness and affordability in different regions and socio-economic contexts in Vietnam.

Only one previous cost-effectiveness analysis of HPV vaccination in Vietnam has been conducted \[[@CR19]\], which used an individual-based Monte Carlo simulation model developed at Harvard University. Like our analysis, the Harvard analysis concluded that HPV vaccination would only be cost-effective at low vaccine prices (below about \$10 per vaccinated girl in north Vietnam and \$50 in south Vietnam). The advantage of our study is that we were able to use actual vaccine prices available to Gavi and on the private market in Vietnam. We were also able to micro-cost cervical cancer treatment costs for the first time, instead of extrapolating costs from Thailand and other Asian countries as was done in the Harvard study.

Vietnam is one of the pioneer countries to use PRIME with WHO support to inform a national cost-effectiveness analysis of HPV vaccination. The tool was found by local analysts to have both positive features and shortcomings. Data and expertise requirements are light, facilitating its use and interpretation by non-experts. This allowed analyses to be led by local investigators in contrast to many previous cost-effectiveness analyses in low and middle-income countries \[[@CR31]\]. However, PRIME underestimates the cost-effectiveness of HPV vaccination by not incorporating herd protection, pre-cancerous health states or non-cervical cancer disease outcomes such as anogenital warts. Also, the Excel-based version lacks built-in features for probabilistic sensitivity analysis, so outputs such as cost-effectiveness acceptability curves have to be constructed based on manual alteration of input parameters. Hence there is scope for future iterations of PRIME to incorporate more advanced features for expert users.

Conclusion {#Sec11}
==========

This is the first cost-effectiveness analysis of HPV vaccination in Vietnam to be led by local analysts and to include a local costing study of cervical cancer treatment. The study highlights the urgency of HPV vaccine implementation in Vietnam during the window of opportunity to obtain Gavi prices. It also demonstrates the importance of HPV vaccine introduction in Gavi-graduating countries before the countries become ineligible for low Gavi prices, after which the vaccination programme may cease to be cost-effective. Finally, our study highlights the need to understand realistic cost-effectiveness thresholds in low and middle-income countries so as to avoid misinforming health policy makers.
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